ENVB - Enveric Biosciences, Inc.

1.15
-0.060   -5.217%

Share volume: 73,296
Last Updated: 04-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.00%

PREVIOUS CLOSE
CHG
CHG%
$1.21
-0.06
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
28%
Profitability 0%
Dept financing 31%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-10.16%
1 Month
-33.14%
3 Months
176.51%
6 Months
177.11%
1 Year
24.99%
2 Year
-14.76%
Key data
Stock price
$1.15
P/E Ratio 
0.00
DAY RANGE
$1.10 - $1.24
EPS 
-$7.37
52 WEEK RANGE
$0.27 - $4.83
52 WEEK CHANGE
$22.18
MARKET CAP 
3.564 M
YIELD 
N/A
SHARES OUTSTANDING 
8.920 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
01-29-2025
NEXT EARNINGS DATE
05-14-2025
BETA 
0.91
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$89,207
AVERAGE 30 VOLUME 
$80,245
Company detail
CEO: Joseph Tucker
Region: US
Website: enveric.com
Employees: 20
IPO year: 2007
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Enveric Biosciences, Inc. engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 for the. treatment of cancer related distress. EV102, a cannabinoid cream for topical skin application; and EV101, a. cannabinoid and chemotherapy combination therapy.

Recent news
loading